10.3389/fmed.2025.1509947 [DOI] [PMC free article] [PubMed] [Google Scholar] Jones M., Cappola J
EMA and the Heads of Medicines Agencies (HMA), through the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG), have issued recommendations to tackle shortages of the glucagon-like peptide-1 (GLP-1) receptor agonists Ozempic (semaglutide), Saxenda (liraglutide), Trulicity (dulaglutide) and Victoza (liraglutide)
This includes providing comprehensive consultations to discuss treatment options, potential side effects, and expected outcomes
Being active was second nature
Benefits may include: Continued appetite control Ongoing fat loss Better consistency with nutrition habits Improvements in weight-related health markers Months 6-12 Long-term treatment may continue supporting weight management goals
To qualify, you should have a body mass index (BMI) of at least 30 (obese) or 27 (overweight) with a weight-related health condition